Literature DB >> 1974510

Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives.

B Krönig1, L Widmann, C Staiger, M Machwirth, U Stienen, M Hennig, B Müller-Beckmann.   

Abstract

Carvedilol and nitrendipine were given for 12 weeks in a double-blind study to 81 elderly patients (greater than or equal to 60 years) with essential hypertension. The effects on blood pressure were measured (Riva Rocci) before medication and after 2 h with the patient in a lying and standing position after 4 weeks of placebo therapy as well as after 4, 8 and 12 weeks of treatment. Carvedilol (25 mg/o.d.) reduced blood pressure measured in the supine and erect position very successfully, similar to the reduction achieved with nitrendipine (20 mg/o.d.), without influencing the pulse rate. Both substances were well tolerated. Carvedilol is an alternative substance for lowering high blood pressure in elderly hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974510     DOI: 10.1007/bf01409490

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

Review 1.  Potential adverse effects of antihypertensive drugs in the elderly.

Authors:  P P Lamy
Journal:  J Hypertens Suppl       Date:  1988-11

2.  Evaluation of cardiovascular risk in the elderly: the Framingham study.

Authors:  W B Kannel; T Gordan
Journal:  Bull N Y Acad Med       Date:  1978-06

3.  Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels.

Authors:  F H Messerli; K Sundgaard-Riise; H O Ventura; F G Dunn; L B Glade; E D Frohlich
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

4.  Place of calcium antagonists in antihypertensive therapy: introduction and round-table discussion.

Authors:  F R Bühler; A Distler; J H Laragh; D Tourkantonis; G Valdes; M A Weber
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

5.  Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee.

Authors: 
Journal:  Hypertension       Date:  1985 May-Jun       Impact factor: 10.190

Review 6.  A new molecule with vasodilating and beta-adrenoceptor blocking properties.

Authors:  U Abshagen
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

  6 in total
  5 in total

Review 1.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 2.  Antihypertensive profile of carvedilol.

Authors:  W Meyer-Sabellek; B Agrawal
Journal:  Clin Investig       Date:  1992

3.  Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Authors:  T Wendt
Journal:  Clin Investig       Date:  1992

4.  A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.

Authors:  U Hauf-Zachariou; L Widmann; B Zülsdorf; M Hennig; P D Lang
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.